Lorvotuzumab
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab) ) is a humanized monoclonal antibody that binds CD56 (NCAM1) . Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1].
Product Specifications
CAS Number
[339306-30-8]
Product Name Alternative
Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)
UNSPSC
12352203
Target
ADC Antibody
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lorvotuzumab.html
Purity
99.77
Solubility
10 mM in DMSO
Smiles
[Lorvotuzumab]
Molecular Weight
(146.44 kDa)
References & Citations
[1]James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126 (24) :5303-5310.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6196989-01 0.1 mL
NR2E1 (Nuclear Receptor Subfamily 2, Group E, Member 1, TLL, TLX, XTLL) (MaxLight 405)
Ask
View Details MBS6196989-02 5x 0.1 mL
NR2E1 (Nuclear Receptor Subfamily 2, Group E, Member 1, TLL, TLX, XTLL) (MaxLight 405)
Ask
View Details 
GTR15280205 1 Vial
Lentiviral mouse Racgap1 shRNA (UAS) - Lentiviral mouse Racgap1 shRNA (UAS) (25)
Ask
View Details 
041594-HRP 200 µL
SERTAD4, CT (SERTAD4, SERTA domain-containing protein 4) (Azide free) (HRP) discontinued
Ask
View Details